Name: Karolinska Institute - BioCentury Company Profiles - BCIQ
Creator: Biocentury

Emerging Company Profile

signInButton

SIGN IN

Find partnering and investment opportunities, uncover and track competitive threats, dive into a company's financing and deal history, its pipeline and molecular targets of interest, and much more. Please note, you are viewing a free version of BCIQ, BioCentury's advanced business intelligence database for the biopharma industry. Request a trial to unlock the full value of BCIQ.

REQUEST A FREE TRIAL

AcquiredOrMerged

Company profiles have been archived if there have been no financings, deals or product updates in BCIQ in the last five years, or the company is out of business.

If you believe a company has been archived in error, please contact us at 

Company profiles have been archived if there have been no financings, deals or product updates in BCIQ in the last five years, or the company is out of business.\nIf you believe a company has been archived in error, please contact us at \nsupport@biocentury.com\n.

Cat-H(AcquiredorMerged)

Historical deals and financings can be found by searching the organization's name in the BCIQ <DEALS> and <FINANCING> Modules.

Default (Company Type Blank)

CategoryHDefault (Company Type Blank)

NonBioPharma

Biopharma related deals can be found by searching the organization's name in the <DEALS> Module.

Cat-H(NonBioPharma)

Biopharma related deals can be found by searching the organization's name in the <DEALS> Module.\n

Karolinska Institute

Unlocking the cellular dynamics of women’s health: Literature Dive

Science Spotlight: Preventing NK cells from rejecting allogeneic therapies, and more

Science spotlight: An antidote to reverse anticoagulants, two ocular gene therapies, and more

Targeting host CCZ1 for endosome-dependent viral infections

Improved CAR immune cell function; plus AlphaMissense and more

An anti-citrullinated protein mAb with therapeutic effects in RA

Pretzel: modulating the mitochondrial genome

Intima’s public neoantigen discovery platform; plus MS autoantigens and more

An in vivo CAR T manufacturing implant; plus Seer, Kither and more

An MTHFD2 inhibitor for AML